Satoshi Noda

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Magnetic Resonance Imaging

Polycyclic Aromatic Hydrocarbons

Epidermal Growth Factor Receptor

Helicobacter Pylori

Top Venues

Clinical pharmacology and therapeutics

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Rika Fukui, Satoshi Noda, Yoshito Ikeda, Yuichi Sawayama, Tomohiro Terada, Yoshihisa Nakagawa, Shin-Ya Morita
Relationships of Proton Pump Inhibitor-Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study. Clinical pharmacology and therapeutics (2024)
Rika Fukui, Satoshi Noda, Yoshito Ikeda, Yuichi Sawayama, Tomohiro Terada, Yoshihisa Nakagawa, Shin-Ya Morita
Relationships of Proton Pump Inhibitor-Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study. Clinical pharmacology and therapeutics 115 (5) (2024)
Rika Fukui, Satoshi Noda, Yoshito Ikeda, Yuichi Sawayama, Tomohiro Terada, Yoshihisa Nakagawa, Shin-Ya Morita
Relationships of Proton Pump Inhibitor-Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study. Clinical pharmacology and therapeutics 115 (5) (2024)
Rika Fukui, Satoshi Noda, Yoshito Ikeda, Yuichi Sawayama, Tomohiro Terada, Yoshihisa Nakagawa, Shin-Ya Morita
Relationships of Proton Pump Inhibitor-Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study. Clinical pharmacology and therapeutics 115 (5) (2024)
Satoshi Noda, Hiroya Iida, Takehide Fujimoto, Yoshinori Wakasugi, Naoki Yabuta, Masatomo Sudou, Daiki Hira, Masaji Tani, Akira Andoh, Shin-Ya Morita, Tomohiro Terada
Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma. Cancer chemotherapy and pharmacology 88 (2) (2021)
Satoshi Noda, Daiki Hira, Rie Osaki, Takehide Fujimoto, Hiroya Iida, Sachiko Tanaka-Mizuno, Akira Andoh, Masaji Tani, Yoshito Ikeda, Shin-Ya Morita, Tomohiro Terada
Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. Cancer chemotherapy and pharmacology 86 (1) (2020)